TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15
- Justin A. Shyer
- Fabien Wehbe
- Christopher D. Davidson
- Hannah S. Bender
- Minh Thai
- Christian Cox
- Alsu Missarova
- Alexander Arlantico
- Ben Hall
- Ruoyu Zhang
- David Kim
- Anthony Altieri
- Shakir Hasan
- Afshin Namdar
- Tina Chen
- Shaheed W. Hakim
- Cynthia Guidos
- Hans D. Brightbill
- Tony Kuo
- Graham Heimberg
- Héctor Corrada Bravo
- Rojo A. Ratsimandresy
- Salil Uttarwar
- Grace Teng
- Omar Salem
- Mehrdad Arjomandi
- Mark S. Wilson
- Spyros Darmanis
- James Ziai
- Alexis Scherl
- Zora Modrusan
- Paul J. Wolters
- Matthew B. Buechler
- Jason A. Vander Heiden
- Shannon J. Turley
2026-05-20
Fibroblasts are key potentiators of chronic disease pathophysiology. Despite their established roles in promoting pathological inflammation and tissue remodeling, activated myofibroblasts are generally characterized as a single, homogeneous cell population, obscuring critical functional distinctions. Defining the cell states, their molecular regulators, and restricted markers is critical to developing effective therapies for the treatment of fibrosis. Here, using a human lung stromal cell atlas of idiopathic pulmonary fibrosis, we identify two myofibroblast transcriptional states associated with distinct predicted biological function, regulation, and cell surface marker expression. We identify fibroblast-specific TGFb signaling as the key regulator of the mechanistic switch from a wound healing–associated and proliferative to a profibrotic myofibroblast. Further, we elucidate conserved TGFb-dependent and suppressed gene expression programs that define these states. Our findings reveal that LRRC15 is highly restricted to myofibroblasts that primarily express an extracellular matrix-remodeling gene program and illuminate that this key cell state can differentiate in the absence of an obligate inflammatory precursor intermediate. Last, we apply machine learning using a human single-cell foundation model to demonstrate broad applicability of the biology described herein to human chronic disease.